- Patrys (PAB) receives $250,000 in funding to support its research on treatments for brain cancer
- The Cure Brain Cancer Foundation allocated the funds to Patrys’ collaborator, Telethon Kids Institute
- The money will be used to identify potential therapeutic applications of PAB’s PAT-DX1 and PAT-DX3 deoxymabs in the management and treatment of brain cancers
- It will be used in both in vitro and in vivo models of high-grade glioma (HCG), with the deoxymabs to be used with standard of care (SOC) treatments
- Shares are trading 4.76 per cent higher at 2.2 cents each just before market close
Patrys (PAB) has been awarded $250,000 in funding to support its research on potential treatments for brain cancer.
The Cure Brain Cancer Foundation allocated the funds to Patrys’ collaborator, Telethon Kids Institute.
The money will be used to identify potential therapeutic applications of PAB’s PAT-DX1 and PAT-DX3 deoxymabs in the management and treatment of brain cancers.
It will be used in both in vitro and in vivo models of high-grade glioma (HCG) — the most common and deadly type of brain cancer — with the deoxymabs to be used with standard of care (SOC) treatments.
The company believes this will block the repair of damaged DNA, resulting in an increase in cancer cell death.
The preclinical research program will be conducted at Telethon Kids Institute.
CEO and Managing Director Dr James Campbell said this is one of the company’s most exciting collaborations to date.
“We hope to grow our relationship with Cure Brain Cancer Foundation, and look forward
to expanding our connections to Australian brain cancer clinicians and researchers as we move towards our expected phase one clinical trial in mid-2023,” he said.
Shares were trading 4.76 per cent higher at 2.2 cents each at 4:03 pm AEST.